vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $196.3M, roughly 1.4× TOOTSIE ROLL INDUSTRIES INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 14.7%, a 81.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 1.5%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 13.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
ACAD vs TR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $196.3M |
| Net Profit | $273.6M | $28.8M |
| Gross Margin | 90.8% | 35.7% |
| Operating Margin | 6.1% | 17.0% |
| Net Margin | 96.3% | 14.7% |
| Revenue YoY | 9.4% | 1.5% |
| Net Profit YoY | 90.3% | 27.9% |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $196.3M | ||
| Q3 25 | $278.6M | $232.7M | ||
| Q2 25 | $264.6M | $155.1M | ||
| Q1 25 | $244.3M | $148.5M | ||
| Q4 24 | $259.6M | $193.4M | ||
| Q3 24 | $250.4M | $225.9M | ||
| Q2 24 | $242.0M | $150.7M | ||
| Q1 24 | $205.8M | $153.2M |
| Q4 25 | $273.6M | $28.8M | ||
| Q3 25 | $71.8M | $35.7M | ||
| Q2 25 | $26.7M | $17.5M | ||
| Q1 25 | $19.0M | $18.1M | ||
| Q4 24 | $143.7M | $22.5M | ||
| Q3 24 | $32.8M | $32.8M | ||
| Q2 24 | $33.4M | $15.6M | ||
| Q1 24 | $16.6M | $15.8M |
| Q4 25 | 90.8% | 35.7% | ||
| Q3 25 | 92.2% | 34.1% | ||
| Q2 25 | 92.2% | 36.4% | ||
| Q1 25 | 91.7% | 35.3% | ||
| Q4 24 | 91.6% | 39.1% | ||
| Q3 24 | 92.5% | 34.1% | ||
| Q2 24 | 92.5% | 33.5% | ||
| Q1 24 | 88.8% | 32.7% |
| Q4 25 | 6.1% | 17.0% | ||
| Q3 25 | 12.8% | 13.9% | ||
| Q2 25 | 12.2% | 7.8% | ||
| Q1 25 | 7.9% | 15.5% | ||
| Q4 24 | 59.1% | 20.0% | ||
| Q3 24 | 12.6% | 15.6% | ||
| Q2 24 | 12.6% | 10.2% | ||
| Q1 24 | 7.4% | 7.3% |
| Q4 25 | 96.3% | 14.7% | ||
| Q3 25 | 25.8% | 15.3% | ||
| Q2 25 | 10.1% | 11.3% | ||
| Q1 25 | 7.8% | 12.2% | ||
| Q4 24 | 55.4% | 11.6% | ||
| Q3 24 | 13.1% | 14.5% | ||
| Q2 24 | 13.8% | 10.4% | ||
| Q1 24 | 8.0% | 10.3% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $176.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $941.0M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $176.6M | ||
| Q3 25 | $258.0M | $119.8M | ||
| Q2 25 | $253.6M | $170.5M | ||
| Q1 25 | $217.7M | $176.6M | ||
| Q4 24 | $319.6M | $194.6M | ||
| Q3 24 | $155.1M | $163.2M | ||
| Q2 24 | $177.1M | $131.2M | ||
| Q1 24 | $204.7M | $159.4M |
| Q4 25 | $1.2B | $941.0M | ||
| Q3 25 | $917.3M | $918.9M | ||
| Q2 25 | $822.4M | $893.1M | ||
| Q1 25 | $765.2M | $879.4M | ||
| Q4 24 | $732.8M | $870.7M | ||
| Q3 24 | $577.2M | $870.2M | ||
| Q2 24 | $516.7M | $841.4M | ||
| Q1 24 | $464.0M | $834.4M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $976.9M | $1.1B | ||
| Q2 24 | $914.1M | $1.1B | ||
| Q1 24 | $855.1M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $73.3M |
| Free Cash FlowOCF − Capex | — | $61.0M |
| FCF MarginFCF / Revenue | — | 31.1% |
| Capex IntensityCapex / Revenue | — | 6.3% |
| Cash ConversionOCF / Net Profit | -0.18× | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $96.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $73.3M | ||
| Q3 25 | $74.3M | $62.2M | ||
| Q2 25 | $64.0M | $-8.5M | ||
| Q1 25 | $20.3M | $3.6M | ||
| Q4 24 | $40.4M | $68.8M | ||
| Q3 24 | $63.2M | $61.3M | ||
| Q2 24 | $25.0M | $-12.6M | ||
| Q1 24 | $29.1M | $21.4M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | $73.9M | $50.7M | ||
| Q2 25 | — | $-16.0M | ||
| Q1 25 | — | $750.0K | ||
| Q4 24 | — | $64.7M | ||
| Q3 24 | $63.2M | $55.8M | ||
| Q2 24 | — | $-16.6M | ||
| Q1 24 | — | $16.9M |
| Q4 25 | — | 31.1% | ||
| Q3 25 | 26.5% | 21.8% | ||
| Q2 25 | — | -10.3% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 33.5% | ||
| Q3 24 | 25.2% | 24.7% | ||
| Q2 24 | — | -11.0% | ||
| Q1 24 | — | 11.0% |
| Q4 25 | — | 6.3% | ||
| Q3 25 | 0.1% | 5.0% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 2.9% |
| Q4 25 | -0.18× | 2.55× | ||
| Q3 25 | 1.03× | 1.74× | ||
| Q2 25 | 2.40× | -0.49× | ||
| Q1 25 | 1.07× | 0.20× | ||
| Q4 24 | 0.28× | 3.06× | ||
| Q3 24 | 1.93× | 1.87× | ||
| Q2 24 | 0.75× | -0.81× | ||
| Q1 24 | 1.76× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
